<DOC>
	<DOCNO>NCT01097083</DOCNO>
	<brief_summary>The hypothesis study median time progression experimental arm 2 month compare placebo arm 1.4 month</brief_summary>
	<brief_title>Coriolus Versicolor Palliative Therapy Compared Placebo Patients With Child-Pugh C Unresectable Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>The diagnosis HCC make either histological examination tumor tissue image evidence typical spaceoccupying lesion liver together serum AFP concentration 500 ng/ml ( normal value , 10 ng/ml ) know carrier hepatitis B C , AFP 400 ng/ml non Hepatitis B C carrier . Patients unresectable HCC amenable liver transplantation local ablative technique suitable conventional systemic therapy ( include sorafenib chemotherapy ) . Patients ChildPugh Class C liver cirrhosis ( ChildPugh Scores 1015 point ) . Patients ChildPugh Class A B liver cirrhosis eligible conventional therapy clinical trial refuse conventional therapy include Life Expectancy least 12 week All patient antiHBc antibody test HBs Ag negative . If antiHBc positive , HBV DNA detection perform determine viral load . An undetectable Hep B DNA level ( DNA level &lt; 12 IU/ml ) presence positive Hep B core total antibody would indicate active hepatitis infection subject would still eligible trial . Age &gt; 21 year . Performance status ECOG 0 2 Patients must normal organ marrow function define : Absolute neutrophil count &gt; 1.5 x 109/L Platelets &gt; 50 x 109/L Haemoglobin &gt; 9.0g/dl Total bilirubin &lt; 51umol/L ( 3 mg /dL ) AST ( SGOT ) /ALT ( SGPT ) &lt; 5 X institutional ULN Creatinine &lt; 1.5 ULN INR &lt; 1.7 prothrombin time ( PT ) &lt; 4 second ULN Patients receive local systemic treatment last 4 week . Measurable disease accord RECIST Ability understand willingness sign write informed consent document . Ability swallow oral medication The effect C versicolor develop human fetus unknown . For reason , woman childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . Patients history prior malignancy distinct site histology HCC except nonmelanoma skin cancer . Any cancer curatively treat 3 year prior entry permit . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , intractable ascites could control medical therapy Prior use C versicolor Yunzhi HCC Patients chemotherapy radiotherapy within 4 week prior enter study recover adverse event due agent administer 4 week earlier Patients use chinese herbal therapy concurrently investigation agent treatment cancer Known history allergic reaction attribute compound similar chemical biologic composition use study . Presence active hepatitis B/C flare . Known history Human Immunodeficiency Virus ( HIV ) Infection Gastrointestinal disease could affect absorption pharmacokinetics study drug determine investigator Psychiatric illness/social situation would limit compliance study requirement . Patients severe depression psychiatric disorder exclude . Known alcohol and/or substance abuser may interfere subject 's participation study evaluation study result . Pregnancy breastfeed subject . All female patient reproductive potential must negative pregnancy test ( serum urine ) within 14 day prior study enrollment must willing use adequate contraception Patients suffer autoimmune disease , patient concomitant longterm immunosuppressant therapy schedule receive bone marrow transplant</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Patients With Child-Pugh C Unresectable Hepatocellular Carcinoma</keyword>
	<keyword>Patients unfit standard therapy</keyword>
</DOC>